Rationale: Cytomegalovirus (CMV) has been a major cause of morbidity and mortality after allogeneic stem cell transplantation (SCT). The importance of the recipient's serological status is paramount. However, the importance of the donor's serological status in CMV seropositive recipients is controversial. We analysed the influence of the donor's CMV status in a large cohort of patients.
INTRODUCTION
CMV has for many years been an important cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (SCT). There has been major advances in antiviral prophylactic strategies [1] [2] [3] and development of new and more sensitive diagnostic techniques allowing better monitoring of patients and early intervention by antiviral therapy [4] [5] [6] . These advances have reduced the risk for CMV as a direct cause of mortality in HLA-identical sibling transplant recipients while it is still substantial in patients receiving transplants from HLA-mismatched or unrelated donors. However, the patient's CMV serological status still has a strong influence on outcome 7 . The influence of the donor's serological status on outcome of transplantation of a CMV seropositive patient has been controversial 8, 9 .
The aim of this analysis was therefore to analyse the influence of donor seropositivity on outcome of allogeneic stem cell transplantation in a large population of CMV seropositive patients.
PATIENTS AND METHODS
The European Group for Blood and Marrow Transplantation (EBMT) has collected data on patients since the 1970-ies. Patients were selected from the EBMT megafile, who were seropositive for CMV and for whom the donor CMV status was known (n=7895). Syngeneic (n=87) and non-HLA-identical family donor transplants (n= 627) were excluded as were 50 patients for whom the donor type was unknown, incorrectly coded or coded as "multiple donor". Thus, 7018 patients were included in the study. 5910 patients had HLA-identical sibling donors and 1108 had unrelated donors. Patient characteristics of the study population are shown in tables 1 and 2.
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Information regarding donor age was available for only 457 patients. Because in many of the patients the "donor age" was not known, a yes/no variable was created indicating whether or not "donor age" was known in a patient. For all outcomes this variable was added to the Cox models evaluated. A confounding effect by selection bias is assessed by comparing the HR of "donor CMV serological status" and other risk factors before and after adjustment for this dichotomous variable. Each model was fitted once more using the actual "donor age" on the subset of patients with a known donor age.
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The risk for chronic GVHD development was assessed in patients alive at day 100 after transplantation by logistic regression.
RESULTS

HLA-identical sibling donor transplant recipients:
Univariate analysis: "Donor CMV serological status" had no significant effect on the outcome after HLA-identical sibling SCT (HR for death 1.04; 95% c.i. 0.95-1.14; p =.37.
The estimated 10-year survival (Kaplan-Meier) was 42% (+-3%) for patients with CMV positive donors and 46% (+-3%) for patients with CMV seronegative donors (figure 1).
There was no effect of donor CMV status on the risk for acute GVHD while patients alive at day 100 with CMV positive donors had a higher risk for chronic GVHD than patients with seronegative donors (38.5% vs.33.3%; p=.01).
Multivariate analyses:
The hazard ratio for death comparing CMV seropositive and seronegative donors was 1.04 (95% c.i. 0.95-1.14; p=.40) after adjusting for "age", "calendar year of transplant", "donor sex" and "diagnostic group". Similarly the HR for TRM was 1.04 (95% c.i. 0.93-1.17; p=.46). In the different diagnostic subgroups the HR for death were 1.01 (95% c.i. 0.90-1.14; p =.83) for acute leukaemia, 1.11 (95% c.i. 0.89-1.39; p=.34) for CML, and 1. Patients receiving grafts from CMV seropositive donors had an improved event free survival (log rank, p=.01; survival estimates 30% ±5% and 22% ±5%) and a decreased treatment related mortality ( fig. 3 ; log rank, p <.001; estimates 49% ±5% and 62% ±6%) compared to patients receiving grafts from CMV seronegative donors. There was no effect of the donor CMV serostatus on the relapse incidence (log rank, p=.50; estimates 62% ±7% and 63% ±8%). There was no effect of the donor CMV serostatus on the risk for acute GVHD or, in patients alive at day 100 for chronic GVHD. There was no impact of "donor CMV serological status" on the risk for relapse (HR 1.08; p=.76). There was no confounding effect of the stage of disease on the effect of CMV donor seropositivity. CMV donor status had no influence on the risk for development of chronic GVHD in patients alive at day 100 (OR 1.4; 95% c.i 0.9-2.1; p=.13). Donor CMV status did not have any effect on survival in patients alive at day 100.
Causes of death:
HLA-identical sibling transplant recipients: 1860 / 4451 patients died in the CMV seropositive donor group compared to 589 / /1454 in the CMV seronegative donor group. 721
For transplanted for other diseases. There was no effect on the relapse incidence in the groups transplanted for acute leukaemia or CML. The protective effect of "donor CMV serological status" was significant in CML patients in chronic phase but a similar trend was seen also in more advanced stages.
HRs associated with the variable indicating whether donor age was unknown or known were close to 1.0 for survival in acute leukaemia (HR=1.2, p=0.12) and CML (HR=0.9; p=0.50) but significant for the patient group with other diseases (HR=1.5; p=0.02). However, adjusting for "donor age known/unknown" did not change the HR's of any other risk factor in the model by more than a few per cent. Thus, the effect of "donor CMV serological status" was not biased by the absence of information on donor age in a large group of the patients. In the subgroup of patients with known donor ages, we included "donor age" in all Cox models as a continuous covariate. A significant detrimental effect of "donor age" on survival and TRM can be detected in the data for the patients with CML but the HR of "donor CMV serological status" was almost identical whether we adjusted for "donor age".
Effects of T-cell depletion:
One possible hypothesis for the effect of "donor CMV serological status" on outcome is that the effect is mediated by CMV specific T-cells. If this hypothesis is correct, T-cell depletion would reduce the favourable effect of donor CMV seropositive status. This possibility was analysed in patients with CML through construction of a multivariate model adding "T-cell depletion, ATG, or neither" as a discrete covariate. Apart from the main effect, interaction terms were added to test for effect modification, i.e., a possible dependence of the effect of donor CMV seropositivity on the presence or absence of T-cells or ATG. The overall interaction effect was significant (p=0.02) indicating that the effect of "donor CMV serological status" is not the same in the three categories. The HR for the donor CMV serological status was different in the T-cell depleted subgroup compared to the other two groups. Moreover, the hazard ratios among the "neither" and "ATG" group did 
DISCUSSION
CMV has been a major cause of transplant related mortality in allogeneic SCT recipients [10] [11] [12] . One of the key risk factors has been patient CMV serological status especially in unrelated donor transplant recipients 7, 8, [13] [14] [15] . CMV seropositive patients have a poorer outcome than CMV seronegative patients despite improvement in preventive strategies against CMV disease such as antiviral prophylaxis and preemptive therapy 7, 15 . CMV is immunosuppressive and has in solid organ transplant recipients been associated with an increased risk for bacterial and fungal infections 16 and prevention of CMV can reduce in a lower risk for bacterial and fungal infections 16, 17 and decreased mortality in infectious complications after SCT 2 .
The influence of the donor CMV serological status to a CMV seropositive patient has been
controversial. An early study in T-cell depleted patients receiving grafts from HLA-identical donors suggested that outcome could be improved by the use of a CMV seropositive donor 9 .
This finding has not been verified in other studies 13 . In this study, we found no influence by CMV serological status on overall survival and transplant related mortality in patients receiving grafts from HLA-identical donors. On the other hand; there was a strong influence by donor CMV serological status on outcome in unrelated donor transplants. Patients receiving grafts from CMV seropositive unrelated donors had improved survival, event free survival, and reduced transplant related mortality. That a possible effect would be stronger in unrelated donor transplant recipients than in HLA-identical sibling graft recipients fits with the results showing that CMV associated mortality and the risk for other infectious causes of transplant related mortality were higher after unrelated than HLA-identical sibling transplantation 10, 14, 18 . Disease stage was of course a highly significant predictor of mortality.
Other factors significant in the multivariate analysis were patient age, calendar year of SCT, and the use of HLA-mismatched unrelated donors. These factors are well recognised from earlier studies.
How was this effect by donor CMV status mediated? The most likely explanation would be death in CMV disease by itself in patients receiving grafts from CMV seronegative donors.
However, although there was a slight trend in this direction with lower risks for death in interstitial pneumonia, this cannot be the entire explanation. CMV has been shown to be immunosuppressive and increase the risk for bacterial and fungal infections in transplant recipients. Indeed by preventing CMV replication, a reduction in mortality due to all types of infections can be achieved 2 . This hypothesis is supported by our data since there was a strong trend for an increased risk for death from infections in patients receiving grafts from CMV seronegative donors.
We have not looked at acute GVHD's effect on outcome in this study since the aim was to evaluate factors known before transplantation thereby allowing a choice of the best donor.
However, we could find no effect by CMV donor status on the risk for acute GVHD.
Analyses of CMV donor status on the risk for chronic GVHD gave different results. There was no effect in patients transplanted with unrelated donors but we could find a significant increase of the risk for chronic GVHD in patients with CML transplanted from CMV seropositive sibling donors. In neither group, landmark analysis of patients alive at day 100
showed any influence of donor CMV status on survival. Thus, the effect on survival and TRM occurs before day 100 at the time when most infectious deaths do occur and is independent of acute and chronic GVHD.
Recently, Kollman et al in a very large study from the National Marrow Donor Program reported that increasing donor age was a significant risk factor for decreased survival in unrelated donor transplants but no effect of CMV donor serological status could be found 19 .
There was a difference in how disease categories were analysed in the two studies. We found that the CMV donor status effect was different in patients transplanted for different diseases and therefore it was not possible to adjust for disease categories as a covariate since it resulted in a violation of the proportional hazard assumption while Kollman et al adjusted for diagnosis. However to allow comparison with the study by Kollman et al., we reran all models in a similar manner as in their paper. It should be stressed that this is of course is statistically incorrect. However with this limitation as well as the limitation of missing data regarding donor age, having a CMV seropositive donor still had a positive impact on survival also when diagnosis was entered into the models.
In our different disease models, there were strong CMV donor status effects in patients with CML and in a mixed group of patients transplanted mainly for MDS, aplastic anaemia, and lymphoma while there was no significant effect in patients with acute leukaemia. The effects were mediated through a lower TRM in both groups. It should be noted that there was a trend for lower TRM also in patients with acute leukaemia who had CMV seropositive donors but it did not translate into an improved survival. There are several different possible explanations to these different effects in different patient categories. Patients with acute leukaemia are more likely to die of relapse and therefore the impact of reducing transplant related mortality is less. A second possibility is that patients with acute leukaemia due to previous chemotherapy might be more prone to die of transplant related causes unrelated to infections. A third possibility for the different effect in patients transplanted for acute leukaemia and CMV is the large difference in age between patients with acute leukaemia (mean age 23.9 years) and CML (mean age 33.7 years). This age difference is mainly due to the presence of many of young children in the acute leukaemia group. The likely mechanism for a negative impact by using a CMV seronegative donor is the lack of transfer of mature CMV specific effector T-cells or the transfer of T-cell precursors able to multiply and reconstitute T-cell immunity. A key element in immune reconstitution after transplantation is thymic function and children have a better post-transplant thymic function than adults [20] [21] [22] and might therefore better be able to mount a CMV-specific immune response 20, 23 . All these three explanations might contribute to the different effect of donor CMV serological status in the different diagnostic subgroups although none of the possibilities can alone explain the differences. 
